What FDA's Animal-Testing Roadmap Actually Means If You're Running NHP Studies

ANEWCRO Research Team

Sep 29

4 min read

FDA's shift away from mandatory animal testing has been building for a few years, but it moved from principle to practice fast in the past twelve months. For a CRO built around nonhuman primate models, that is not a headline to talk around. It is worth being specific about what has actually changed, what is still pending, and where NHP models still do something the alternatives cannot.

What's Actually Changed, With Dates

The legal foundation was set by the FDA Modernization Act 2.0, signed into law December 29, 2022, which removed the long-standing requirement that new drugs be tested on animals before human trials. FDA's April 2025 roadmap is where that law turned into a phased plan, starting with monoclonal antibodies and expanding to other modalities from there.

FDA's own reasoning leans on a specific, citable statistic: over 90% of drugs that appear safe and effective in animal studies do not go on to receive FDA approval in humans, predominantly due to safety or efficacy issues animal models did not predict (Marshall et al., Altern Lab Anim, 2023). That is the evidence base driving the roadmap, not just a cost or timeline argument.

Two draft guidances have since put that plan into concrete technical detail: Monoclonal Antibodies: Streamlined Nonclinical Safety Studies (December 2025), and the broader General Considerations for the Use of New Approach Methodologies in Drug Development (March 2026), which extends the same thinking beyond mAbs to NAM use across drug development generally.

FDA reported hitting its Year 1 goals in April 2026: the mAb draft guidance above, an updated horseshoe crab endotoxin testing guidance expected to spare over a million animals a year, a new searchable database of acceptable alternative methods, the agency's first qualified AI-based drug development tool, and new international regulator collaboration on the same standards.

Where NAMs Genuinely Help

For well-characterized biologics with predictable, single-target mechanisms, in vitro and in silico systems can now answer some safety questions faster, with fewer animals, and in some cases with results more directly relevant to human biology than an animal proxy provides. That is a legitimate scientific advance, not just a regulatory cost-saving measure, and it deserves to be treated as one.

The Other Half: Model-Informed Drug Development

NAMs generate data. Model-Informed Drug Development, or MIDD, is what increasingly turns that data into something a regulator or a program team can act on. Physiologically based pharmacokinetic (PBPK) modeling and quantitative systems pharmacology (QSP) modeling let sponsors simulate human PK, safety, and efficacy profiles in silico, using nonclinical and in vitro inputs, prior compound knowledge, and known biology, rather than generating every data point from a new animal study.

In practice, that shows up as PBPK models supporting first-in-human dose selection, justifying a drug-drug interaction assessment without a dedicated animal study, or bridging a formulation or pediatric dose without a full repeat study. It is one reason FDA guidance increasingly references model-informed approaches alongside NAMs rather than treating them as separate topics.

The honest caveat applies here too: MIDD rarely eliminates animal testing outright today. It more often reduces, refines, or supplements it, filling gaps a NAM alone cannot answer and adding a layer of predictive translation on top of whatever nonclinical data does get generated.

Where NHP Models Still Do Something NAMs and Modeling Cannot Yet

CNS programs requiring intrathecal, intracisternal, or intracerebroventricular dosing and CSF sampling, where whole-organism distribution matters
Ocular studies depending on eye anatomy at a scale only a few species share with humans, alongside OCT and IOP assessment
Complex PK/PD in biologics and gene therapies, where systemic immune response and clearance dynamics are the entire question
Immunogenicity assessment, where anti-drug antibody responses only really surface in a live, intact immune system

FDA Says the Same Thing

This is not just our position. FDA's own October 2024 report to its Science Board on integrating alternative methods is explicit about the current limits of NAMs, and by extension the modeling built on top of them:

Technical limitations to current NAMs exist and, today, no assays fully capture the critical hazard endpoints for assessing all currently existing human or animal organ systems; therefore, NAMs cannot fully eliminate the use of integrated physiological systems such as in animal and human trials.

That is the regulator that wrote the roadmap saying, in its own report, that whole-organism models still have a job to do, and that both NAMs and the modeling built on them will need continued validation before regulators can lean on them further.

One More Thing Worth Watching

Separately from FDA's own guidance process, Congress has been moving FDA Modernization Act 3.0 through both chambers in 2026 (it passed the House in July and the Senate by unanimous consent), which would further codify NAM adoption if it is signed into law. It has not been signed as of this writing, so treat it as directionally important rather than settled policy for now.

Our Take

We read all of this as a call to be more precise about when an NHP model is the right tool, not a reason to defend using one by default, and as a reason to get fluent in MIDD ourselves rather than treating it as someone else's discipline. The programs where primate models still matter are the ones where the science, not habit, keeps them there.

Learn more about our toxicology and safety assessment and PK/PD work.